JPRN-UMIN000009911已完成1 期
A phaseI/II study of irinotecan with bevacizumab as second line treatment of elderly patients with metastatic colorectal cancer. - A phaseI/II study of irinotecan with bevacizumab as second line treatment of elderly patients with metastatic colorectal cancer.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Need to drain malignant celomic fluid. (2)Jaundice (3)Paralytic or mechanical bowel obstruction. (4)Receiving Atazanavir Sulfate (5)Radiological evidence of CNS metastases or brain cancer. (6)Multiple primary cancers within 5 years. (7)Complication of cerebrovascular disease or symptoms within 1 year. (8)Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week. (9)Administering antithrombotic drug within 10 days. (10)Need to administrate or having anti-platelets therapy (including Methotrexate aspirin and NSAIDS). (11)Evidence of bleeding diathesis or coagulopathy. (12)Active gastrointestinal ulcer (13)Current or previous (within the last 1 year) history of GI perforation. (14)Non healing fracture (15)Renal failure to be treated,3+ or higher proteinuria within 2 weeks prior to entry. (16)Uncontrolled Hypertension (17)Uncontrolled diabetes mellitus (18)Clinically significant (i.e. active) cardiovascular disease or past or current history (within the last 1 year) of myocardial infarction. (19)History of the serious hypersensitivity for bevacizumab. (20)Evidence of interstinal lung disease, or pulmonary fibrosis. (21)History of organ transplantation. (22)Treatment history of irinotecan. (23)Other conditions not suitable for this study.
研究者
相似试验
已完成
2 期
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.colorectal cancerJPRN-UMIN000009910Tsuchiura kyodo general hospital25
已完成
2 期
Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.Metastatic colorectal cancer.JPRN-UMIN000008947Epidemiological and Clinical research Information Network (ECRIN)40
已完成
2 期
Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumabJPRN-UMIN000005228Tokyo Women's Medical University33
招募中
不适用
Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumabadvanced colorectal cancerJPRN-UMIN000007065Toyama Prefectural Central Hospital Department of Gastroenterology33
已完成
1 期
A phase I study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatiMetastatic colorectal cancerJPRN-UMIN000019828Pharma Valley Center21